Overview

Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease

Status:
Completed
Trial end date:
2017-11-02
Target enrollment:
Participant gender:
Summary
To evaluate the safety pharmacokinetics, and pharmacodynamics of repeat weekly dosing of MEDI6012 in subjects with stable atherosclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
MedImmune LLC